🇺🇸 FDA
Pipeline program

Delayed and extended release mesalazine

SPD476-301

Phase 3 small_molecule completed

Quick answer

Delayed and extended release mesalazine for Colitis, Ulcerative is a Phase 3 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Colitis, Ulcerative
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials